Global Blood Plasma Market

Transcription

1 Global Blood Plasma Market

2 Executive Summary Plasma is a composite mixture of more than 700 proteins and other substances which are vital for the smooth functioning of the human body. Plasma is the liquid component of blood, constituting around 50% of the total blood volume. Plasma in itself is approximately 90% water, with the remaining 10% comprising of proteins, minerals, clotting factors, hormones, and immunoglobins. Plasma is the raw material for the extraction of various proteins which are used for their therapeutic values. Plasma proteins cannot be manufactured rather the same are obtained or collected from a large pool of donors. With the swift progression in the field of biomedical/healthcare technology, companies operating in the healthcare/pharmaceutical/therapeutic industry are now surmounting in the respective realm. Also, on account of the escalating incidences of health related issues originating due to changing lifestyle and continuously changing surroundings, blood plasma industry s growth is augmented. In order to address the unmet medical needs related to blood disorders, autoimmune diseases and liver function impairment among others, associated companies are coming up with novel and improved treatment options like IVIG, albumin, clotting factors etc. which are derived from human blood plasma. The blood plasma industry is highly regulated to ensure the safety of collected plasma and protect donors. The market is characterized by fast pace developments in the clinical technology and testing methodology. This report elicits the global blood plasma market with focus on segmental markets like IVIG, albumin and hemophilia market. Also the regions including the US and China are covered. Moreover, market dynamics like the key trends, industry developments, growth drivers and challenges are analyzed in detail. Furthermore, the competitive landscape of the industry is highlighted. The rivalry prevalent in the global blood plasma market is quite fierce with numerous local and global players contenting for the market share. On the global front, the key players are Baxter, CSL, Grifols and Octapharma.

3 The normal composition of human blood is: Plasma, Red Blood Cells (RBC), White Blood Cells (WBC) and Platelets Global Blood Plasma Market ( ) The global blood plasma market was valued at US$...billion in 2010, and reached US$... billion in 2011, depicting an increase of.% approximately. The recorded CAGR over the cited period was.%. In terms of products, in 2011, the global blood plasma market was dominated by IVIGs or IGs with a significant share of..% followed by FVIII with.% share. FIX and albumin constituted % share each. The plasma derivatives sales in the US stood at US$... billion in 2011, witnessing an increase of..% approximately over the value of US$... billion in The manufacturing cost structure of plasma fractionation is such that the major portion of the cost, approximately..%, is constituted by plasma product. Global Plasma Market Share by Product (2011) Plasma Derivative Sales in the US ( ) IG Factor VIII Factor IX Albumin Other Products

4 Plasma is the raw material for the extraction of various proteins. It can be divided into two categories depending on how it is obtained viz. Source plasma and Recovered plasma... Tonnes Global IVIG Market Size ( ) IVIG Market Volume by Region (2005, 2008 and 2011) As of 2011, the global sales of immunoglobulins stood at US$... billion, registering a modest growth of.% over the value of For the period of 7 years spanning from 2004 to 2011, the global IVIG market recorded an impressive CAGR of %. In terms of IVIG market size by volume, the US accounted for the maximum share with..tonnes of IVIG, followed by the EU with.tonnes of contribution in the global IVIG market as of In terms of value, the U.S. market was worth..billion approximately in The IVIG market in the US stood at US$...billion in 2011, recording an increase of nearly..% over US$... billion worth sales generated in The CAGR recorded over the cited period was..%. Sales of IVIG in the US ( ) ) USA EU RoW

5 In frozen condition, plasma can keep for up to 10 years, making it an extremely stable blood product. Also, it can be packaged in dried form for reconstitution US$ Million Global Hemophilia Treatment Market Revenues ( ) Global Plasma Market Share by Company (2011) Grifols Baxter Others- for profit CSL Octapharma Others- for non profit Albumin Market Size of the US and China USA China The global hemophilia treatment market revenues has been moving on an aggressive growth path, registering an increase of US$...billion to US$...billion by 2012 as compared to US$... billion in As of October 2012, the albumin market of China was worth US$. million while the same in the US was worth US$...million only. As of 2011, the global plasma market was led by Grifols with 20% share, followed by CSL and Baxter with shares worth % and..%, respectively. Octapharma accounted for % share in the same. The opportunity for global blood plasma market is anticipated to be US$... billion for the year The respective market is poised to record a growth of % in 2012 as compared to the value of US$...billion in The global blood plasma market is projected to grow at a CAGR of.% over the period of three years spanning from 2012 to 2015 and estimated to reach US$... billion by the end of Note: Market attractiveness is inverse of penetration. Low penetration means high attractiveness and vice-versa